Electrode catheter ablation of resistant ventricular tachycardia in arrhythmogenic right ventricular dysplasia

Fontaine, G.; Frank, Robert; Rougier, I.; Tonet, Joelci; Gallais, Y; Farenq, G.; Lascault, G; Lilamand, Matthieu; Fontaliran, F; Chomette, G; Grosgogeat, Y

doi:10.1007/bf02059913

Cited by 7 publications

(1 citation statement)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a rare heart muscle disorder that causes sudden cardiac death in young asymptomatic people [1]. Histologically, it is defined by myocardial cell death and fibrofatty replacement, but inflammatory myocardial infiltrates are also reported in 60-80% of post-mortem/transplant cardiac specimens [2][3][4][5][6]. Although reports from biopsies in these patients have described inflammatory infiltrates, studies examining myocardial inflammation in vivo using non-invasive techniques are lacking [7].…”

Section: Introductionmentioning

confidence: 99%

Prevalence of 18F-fluorodeoxyglucose positron emission tomography abnormalities in patients with arrhythmogenic right ventricular cardiomyopathy

Protonotarios

Wicks

Ashworth

et al. 2019

International Journal of Cardiology

View full text Add to dashboard Cite

Background Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) is a heritable heart muscle disease that causes sudden cardiac death in the young. Inflammatory myocardial infiltrates have been described at autopsy and on biopsy, but there are few data on the presence of myocarditis in living patients with ARVC using non-invasive imaging techniques. FDG-PET is a validated technique for detecting myocardial inflammation in clinically suspected myocarditis. We aimed to determine the prevalence of myocardial inflammation in patients with ARVC using 18 Ffluorodeoxyglucose positron emission tomography (FDG-PET). Methods and Results We performed a retrospective analysis of a single centre cohort of patients with ARVC referred for FDG-PET scans between 2012 and 2017 for investigation of symptoms or suspected device infection. Sixteen patients (12 male; age 42±13 years) with a definite diagnosis of ARVC were identified. Seven had positive FDG-PET scans, two of whom had cardiac sarcoidosis on endomyocardial biopsy. Of the remaining five, two carried pathogenic desmoplakin mutations. FDG uptake was found in the left ventricular myocardium in all cases. One patient also had right ventricular uptake. Conclusion In this exploratory study, we show that some patients with ARVC have evidence for myocardial inflammation on FDG-PET, suggesting that myocarditis plays a role in disease pathogenesis.

show abstract

Section: Introductionmentioning

confidence: 99%

Prevalence of 18F-fluorodeoxyglucose positron emission tomography abnormalities in patients with arrhythmogenic right ventricular cardiomyopathy

Protonotarios

Wicks

Ashworth

et al. 2019

International Journal of Cardiology

View full text Add to dashboard Cite

show abstract

Differentialtherapie der arrhythmogenen rechtsventrikulären Kardiomyopathie

Wichter

Borggrefe

Block

et al. 1998

Herzschrittmachertherapie und Elektrophysiologie

View full text Add to dashboard Cite

Radiofrequency catheter ablation of ventricular tachycardia in arrhythmogenic right ventricular dysplasia/cardiomyopathy using non-contact electroanatomical mapping: single-center experience with follow-up up to median of 30 months

Nair

Yaduvanshi

Kataria

et al. 2011

J Interv Card Electrophysiol

View full text Add to dashboard Cite

Objective of studyTo evaluate the efficacy of radiofrequency ablation (RFA) of ventricular tachycardia (VT) using non-contact electro-anatomic mapping in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C).MethodsFifteen consecutive patients (44 ± 15 years) with ARVD/C and symptomatic VTs were studied. Eight patients had syncopal VTs. Two patients had recurrent VT while on AICD; in three patients, RFA was done prior to AICD implantation, and ten patients refused AICD. After obtaining activation maps, first, the clinical VT was targeted, and then, other VTs were sought.ResultsTwenty-five inducible VTs were mapped, and 22 of them were successfully ablated. In 13 out of 15 patients, all the clinical and inducible VTs were ablated. In two patients, non-clinical inducible VTs could not be ablated. At 25 ± 16 months (2–52 months), all patients remained asymptomatic. Antiarrhythmic medications were discontinued after 6 months. Two patients had recurrence of non-clinical VT on follow-up. There were no episodes of asymptomatic VT recorded in five patients with AICD.ConclusionA majority of induced VT in patients with ARVD/C can be successfully mapped and ablated using the non-contact Ensite Array Mapping system with good long-term VT-free outcome. Ablation can be a useful adjunct to AICD implantation in such patients.

show abstract

Electrode catheter ablation of resistant ventricular tachycardia in arrhythmogenic right ventricular dysplasia

Cited by 7 publications

References 31 publications

Prevalence of 18F-fluorodeoxyglucose positron emission tomography abnormalities in patients with arrhythmogenic right ventricular cardiomyopathy

Prevalence of 18F-fluorodeoxyglucose positron emission tomography abnormalities in patients with arrhythmogenic right ventricular cardiomyopathy

Differentialtherapie der arrhythmogenen rechtsventrikulären Kardiomyopathie

Radiofrequency catheter ablation of ventricular tachycardia in arrhythmogenic right ventricular dysplasia/cardiomyopathy using non-contact electroanatomical mapping: single-center experience with follow-up up to median of 30 months

Contact Info

Product

Resources

About